Research ArticleBRAIN TUMORS

KHS101 disrupts energy metabolism in human glioblastoma cells and reduces tumor growth in mice

See allHide authors and affiliations

Science Translational Medicine  15 Aug 2018:
Vol. 10, Issue 454, eaar2718
DOI: 10.1126/scitranslmed.aar2718

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

A serendipitous metabolic target for glioblastoma

Glioblastoma (GBM), one of the most aggressive brain cancers, is associated with poor prognosis and low survival rate. GBM stem cells contribute to aggressive GBM growth. Polson et al. hypothesized that promoting neural differentiation could have therapeutic effects. While testing the therapeutic properties of the small-molecule KHS101, previously shown to promote neural differentiation, the authors made the serendipitous discovery that KHS101 exerted cytotoxic activity in multiple patient-derived GBM cell lines by disrupting cell metabolism and promoting autophagy. In vivo administration of KHS101 reduced tumor growth and prolonged survival in patient-derived xenograft mouse models of GBM. The authors suggest that targeting cell metabolism using small molecules might be effective for treating GBM.